<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075660</url>
  </required_header>
  <id_info>
    <org_study_id>I161</org_study_id>
    <secondary_id>CAN-NCIC-IND161</secondary_id>
    <secondary_id>CDR0000347409</secondary_id>
    <nct_id>NCT00075660</nct_id>
  </id_info>
  <brief_title>3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma</brief_title>
  <official_title>A Phase II Study of Triapine (NSC 663249) in Previously Untreated Patients With Recurrent Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as 3-AP, work in different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of 3-AP in treating patients who have&#xD;
      locally recurrent or metastatic renal cell (kidney) carcinoma (cancer).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of 3-AP (Triapine®), in terms of objective response rate, in&#xD;
           patients with previously untreated locally recurrent or metastatic renal cell carcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the adverse events and tolerability of this drug in these patients.&#xD;
&#xD;
        -  Determine the time to disease progression and overall survival of patients treated with&#xD;
           this drug.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, multicenter study.&#xD;
&#xD;
      Patients receive 3-AP (Triapine®) IV over 2 hours on days 1-4 and 15-18. Treatment repeats&#xD;
      every 28 days for up to 6 courses (for stable patients) in the absence of disease progression&#xD;
      or unacceptable toxicity. Patients who achieve a complete response (CR) receive 1 additional&#xD;
      course after documentation of CR. Patients who achieve a partial response (PR) receive 2&#xD;
      additional courses after documentation of stable PR.&#xD;
&#xD;
      Patients are followed every 4 weeks until relapse and then every 3 months for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2004</start_date>
  <completion_date type="Actual">September 22, 2008</completion_date>
  <primary_completion_date type="Actual">October 4, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">19</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed renal cell carcinoma&#xD;
&#xD;
               -  Locally recurrent OR metastatic disease&#xD;
&#xD;
               -  Incurable by standard therapy&#xD;
&#xD;
          -  Clinically and/or radiologically measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion* at least 20 mm by x-ray, physical&#xD;
                  exam, or non-spiral CT scan OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  If the sole site of measurable disease is in a previously irradiated field, there&#xD;
                  must be documented disease progression at that site NOTE: *Bone lesions are not&#xD;
                  considered measurable disease&#xD;
&#xD;
          -  No documented brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No glucose-6-phosphate dehydrogenase (G6PD) deficiency* NOTE: *Screening for G6PD&#xD;
             deficiency is required for patients of African, Asian, or Mediterranean descent&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST or ALT no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No active cardiomyopathy&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary disease requiring oxygen&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No known hypersensitivity to compounds of similar chemical or biological composition&#xD;
             to 3-AP (Triapine®)&#xD;
&#xD;
          -  No active uncontrolled or serious infection&#xD;
&#xD;
          -  No immunodeficiency&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other prior malignancy except adequately treated nonmelanoma skin cancer,&#xD;
             curatively treated carcinoma in situ of the cervix, or other curatively treated solid&#xD;
             tumor with no evidence of disease for at least 5 years&#xD;
&#xD;
          -  No history of significant neurologic or psychiatric disorder (e.g., uncontrolled&#xD;
             psychotic disorders) that would preclude giving informed consent or complying with&#xD;
             study requirements&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No other serious illness or medical condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 3 months since prior interferon for advanced or recurrent disease&#xD;
&#xD;
          -  No other prior immunotherapy for advanced or recurrent disease&#xD;
&#xD;
          -  No prior gene therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior systemic chemotherapy for advanced or recurrent disease&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy (except low-dose nonmyelosuppressive&#xD;
             radiotherapy) and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior investigational anticancer agents&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapy&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
&#xD;
               -  Concurrent nontherapeutic warfarin or heparin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Knox, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sunnybrook Regional Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L-4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA. Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest New Drugs. 2007 Oct;25(5):471-7. Epub 2007 Mar 28.</citation>
    <PMID>17393073</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

